Cargando…

Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12

BACKGROUND: G47∆ is a triple-mutated oncolytic herpes simplex virus type 1 (HSV-1) recently approved as a new drug for malignant glioma in Japan. As the next-generation, we develop armed oncolytic HSV-1 using G47∆ as the backbone. Because oncolytic HSV-1 elicits specific antitumor immunity, interleu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukuhara, Hiroshi, Sato, Yuzuri Tsurumaki, Hou, Jiangang, Iwai, Miwako, Todo, Tomoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039936/ https://www.ncbi.nlm.nih.gov/pubmed/36966232 http://dx.doi.org/10.1038/s43856-023-00270-4

Ejemplares similares

Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation
por: Yamada, Tomoharu, et al.
Publicado: (2020)

Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis
por: Uchihashi, Toshihiro, et al.
Publicado: (2021)

Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma
por: Yajima, Shoh, et al.
Publicado: (2021)

Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation
por: Sugawara, Kotaro, et al.
Publicado: (2021)

Triple‐mutated oncolytic herpes virus for treating both fast‐ and slow‐growing tumors
por: Fukuhara, Hiroshi, et al.
Publicado: (2021)

Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models
por: Inoue, Kosuke, et al.
Publicado: (2023)

Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer
por: Sugawara, Kotaro, et al.
Publicado: (2020)

Oncolytic virus therapy: A new era of cancer treatment at dawn
por: Fukuhara, Hiroshi, et al.
Publicado: (2016)

A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma
por: Todo, Tomoki, et al.
Publicado: (2022)

Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models
por: Matsushima, Hideyuki, et al.
Publicado: (2019)

Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
por: Todo, Tomoki, et al.
Publicado: (2022)

Third‐generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice
por: Nakatake, Richi, et al.
Publicado: (2018)

Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models
por: Hatta, Masahiko, et al.
Publicado: (2022)

Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer
por: Sato, Yuzuri Tsurumaki, et al.
Publicado: (2014)

Designing herpes viruses as oncolytics
por: Peters, Cole, et al.
Publicado: (2015)

Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer
por: Matsumura, Shuichi, et al.
Publicado: (2021)

Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer
por: Kato, Tomoya, et al.
Publicado: (2021)

Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer
por: Kato, Tomoya, et al.
Publicado: (2021)

A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma
por: Takaoka, Hiroo, et al.
Publicado: (2011)

Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity
por: Xie, Jun, et al.
Publicado: (2023)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Entry of Oncolytic Herpes Simplex Virus into Human Squamous Cell Carcinoma Cells by Ultrasound
por: Okunaga, Shusuke, et al.
Publicado: (2015)

Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma
por: Chalise, Lushun, et al.
Publicado: (2022)

Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts
por: Liu, Sisi, et al.
Publicado: (2020)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
por: Thomas, Suzanne, et al.
Publicado: (2019)

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs
por: Braidwood, Lynne, et al.
Publicado: (2013)

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021)

Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors
por: Yamada, Tomoharu, et al.
Publicado: (2022)

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
por: Havunen, Riikka, et al.
Publicado: (2016)

IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity
por: Yang, Min, et al.
Publicado: (2021)

Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
por: Yura, Yoshiaki
Publicado: (2017)

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021)

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
por: Hong, Bangxing, et al.
Publicado: (2022)

A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy
por: Hu, Han, et al.
Publicado: (2022)

Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment
por: Zhang, Nianchao, et al.
Publicado: (2022)

Cowpox Virus: A New and Armed Oncolytic Poxvirus
por: Ricordel, Marine, et al.
Publicado: (2017)

Treatment of breast cancer stem cells with oncolytic herpes simplex virus
por: Li, J, et al.
Publicado: (2012)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013)

Tumour-specific triple-regulated oncolytic herpes virus to target glioma
por: Delwar, Zahid M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7banisfbaah4r5n8dkpfq70h7h